Health economics of rotavirus immunization in Vietnam: Potentials for favorable cost-effectiveness in developing countries

Vaccine

Volumn 30, Issue 8, 2012, Pages 1521-1528

  Tu, Hong Anh T ^a   Rozenbaum, Mark H ^a   Coyte, Peter C ^b   Li, Shu Chuen ^c   Woerdenbag, Herman J ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Affordability; Cost effectiveness; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; ROTAVIRUS INFECTION; VACCINATION; VIET NAM;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; MALE; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED; VIETNAM;

EID: 84856569145     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.052     Document Type: Article

References (43)

1. Kosek M., Bern C., Guerrant R.L. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003, 81(3):197-204.
2. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9(May (5)):565-572.
3. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., Steele D., et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009 Nov 1, 200(Suppl 1):S9-S15.
4. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(August (9741)):615-623.
5. Nguyen V.M., Nguyen V.T., Huynh P.L., Dang D.T., Nguyen T.H., Phan V.T., et al. The epidemiology and disease burden of rotavirus in Vietnam: sentinel surveillance at 6 hospitals. J Infect Dis 2001, 183(June (12)):1707-1712.
6. Van M.N., LuanlT, Trach D.D., Thanh N.T., Van Tu P., Long N.T., et al. Epidemiological profile and burden of rotavirus diarrhoea in Vietnam: 5 years of sentinel hospital surveillance, 1998-2003. J Infect Dis 2005, 192(September (Suppl. 1)):S127-S132.
7. Fischer T.K., Anh D.D., Antil L., Cat N.D., Kilgore P.E., Thiem V.D., et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005, 192(November (10)):1720-1726.
8. Kim S.Y., Goldie S.J., Salomon J.A. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 2009, 9:29.
9. Postma M.J., Jit M., Rozenbaum M.H., Standaert B., Tu H.A., Hutubessy R. Comparative review of three cost-effectiveness models for rotavirus vaccines in National Immunization Programs: a generic approach applied to various regions in the world. BMC 2011.
10. Rozenbaum M.H., Mangen M.J., Giaquinto C., Wilschut J.C., Hak E., Postma M.J. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011, 11(June (1)):462.
11. 2011. Ref Type: Internet Communication. http://www.gavi.org/.
12. UNICEF. Available from the website: ; 2011 [accessed 22.04.2011]. Ref Type: Internet Communication. http://www.unicef.org/infobycountry/vietnam_statistics.html.
13. World Health Organization. Available from the website: ; 2011 [accessed on 2.05.2011]. Ref Type: Internet Communication. https://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/index.html.
14. Anh D.D., Thiem V.D., Fischer T.K., Canh D.G., Minh T.T., Tho le H., et al. The burden of rotavirus diarrhea in Khanh Hoa Province Vietnam: baseline assessment for a rotavirus vaccine trial. Pediatr Infect Dis J 2006, 25(January (1)):37-40.
15. Ministry of Health in Vietnam. Available from the website: ; 2011 [accessed on 2.05.2011]. Ref Type: Internet Communication. http://www.moh.gov.vn/.
16. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(January (1)):11-22.
17. Bilcke J., Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27(4):281-297.
18. Goossens L.M., Standaert B., Hartwig N., Hovels A.M., Al M.J. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008, 26(February (8)):1118-1127.
19. Jit M., Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007, 25(May (20)):3971-3979.
20. Jit M., Bilcke J., Mangen M.J., Salo H., Melliez H., Edmunds W.J., et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27(October (44)):6121-6128.
21. Jit M., Mangen M.J., Melliez H., Yazdanpanah Y., Bilcke J., Salo H., et al. An update to " The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe" Vaccine 2010, 28(November (47)):7457-7459.
22. Murray C.J., Shengelia B., Gupta N., Moussavi S., Tandon A., Thieren M. Validity of reported vaccination coverage in 45 countries. Lancet 2003, 362(September (9389)):1022-1027.
23. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(January (1)):23-33.
24. Dennehy P.H., Vesikari T., Matson D.O., Itzler R.F., Dallas M.J., Goveia M.G., et al. Efficacy of the pentavalent rotavirus vaccine RotaTeq(R) (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccine 2011, 7(May (5)).
25. Ministry of Health in Vietnam. Report on Expanded Programme on Immunization in Vietnam. 2011.
26. Mathers C.D. LAMC. The burden of disease and mortality by condition: data, methods and results for 2001. Global burden of disease and risk factors 2006, 45-240. Oxford University Press, New York. A. Lopez, C. Mathers, M. Ezzati, D. Jamison, C.J.L. Murray (Eds.).
27. Briggs A. CKSM. Making decision models probabilistic. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford.
28. Sendi P.P., Briggs A.H. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001, 10(October (7)):675-680.
29. WHO. The World Health Report 2002. Available from: ; 2010 [accessed 19.04.2010]. Ref Type: Internet Communication. http://www.who.int/whr/2002/en.
30. National Institute of Hygiene and Epidemiology. Ministry of Health in Vietnam. Report on Expanded Programme on Immunization 2009. 2009.
31. Anh D.D., Van Trang N., Thiem V.D., Anh N.H., Hien D.N., Luan T.L., et al. Tinh an toan cua vacxin Rotavin-M1 san xuan tai Polyvac tren nguoi lon tinh nguyen. Tap chi Y hoc Du phong 2011, 7(115):19-28.
32. Luan L.T., Hien N.D., Thiem V.N., Anh D.D., et al. Nghien cuu tien lam sang vacxin rota san xuat tai Vietnam. Tap chi Y hoc Du phong 2011, XVIII(7(99)):50-55.
33. Hien N.D., Quy N.T., Hanh T.B., Luan L.T. Tinh on dinh nhiet cua vaccine rota san xuat tai Vietnam. Tap chi Y hoc Du phong 2010, XX(5(113)):13-18.
34. Hien N.D., Nguyen B.D., Hanh T.B., Luan L.T. Tinh on dinh nhiet vaccine Rotavin-M1 san xuat tai Vietnampp. Tap chi Y hoc Du phong 2010, XX(5(113)):19-22.
35. Van Trang N., Thiem V.D., Anh N.T.H., Hoang L.H., Hien D.N., Luan T.L., et al. Tinh sinh mien dich cua vaccine Rotavin-M1 tre tre 6 den 12 tuan tuoi o Phu Tho va Thai Binh. Tap chi Y hoc Du phong 2011, XXI(2(120)):112-123.
36. Thiem V.D., Trang D.V., Anh N.T.H., Hoang L.H., Hien D.N., Luan T.L., et al. Tinh an toan cua vaccine Rotavin-M1 tren tre 6 den 12 tuan tuoi o Phu Tho va Thai Binh. Tap chi Y hoc Du phong 2011, XXI(2(120)):99-111.
37. Berry S.A., Johns B., Shih C., Berry A.A., Walker D.G. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010, 202(September (Suppl.)):S108-S115.
38. De la Hoz F., Alvis N., Narvaez J., Cediel N. Potential epidemiological and economic impact of two rotavirus vaccines in Colombia. Vaccine 2010, 28(22):3856-3864.
39. de Soarez P.C., Valentim J., Sartori A.M., Novaes H.M. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008, 23(April (4)):221-230.
40. Tate J.E., Rheingans R.D., O'Reilly C.E., Obonyo B., Burton D.C., Tornheim J.A., et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya. J Infect Dis 2009, 200(November (Suppl. 1)):S76-S84.
41. Wilopo S.A., Kilgore P., Kosen S., Soenarto Y., Aminah S., Cahyono A., et al. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Vaccine 2009, 27(November (Suppl. 5)):F67-F74.
42. Naficy A.B., Trach D.D., Ke N.T., Chuc N.T., Sorkin A., Rao M.R., et al. Cost of immunization with a locally produced, oral cholera vaccine in Vietnam. Vaccine 2001, 19(June (27)):3720-3725.
43. Merck. Available from the website: ; 2011 [accessed 4.06.2011]. http://www.merck.com/.